Compare MDGL & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | ONTO |
|---|---|---|
| Founded | 2011 | 1940 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.9B |
| IPO Year | 2005 | 1995 |
| Metric | MDGL | ONTO |
|---|---|---|
| Price | $438.00 | $183.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $674.45 | $229.38 |
| AVG Volume (30 Days) | 326.5K | ★ 868.2K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.70 | $26.63 |
| Revenue Next Year | $46.88 | $16.26 |
| P/E Ratio | ★ N/A | $69.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $265.00 | $89.40 |
| 52 Week High | $615.00 | $232.49 |
| Indicator | MDGL | ONTO |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 38.48 |
| Support Level | $416.43 | $180.18 |
| Resistance Level | $446.51 | $229.81 |
| Average True Range (ATR) | 16.19 | 10.67 |
| MACD | 2.27 | -4.13 |
| Stochastic Oscillator | 61.72 | 14.67 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.